Oncology

The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.

OS with the PSA-targeted, poxvirus-based cancer vaccine was no better than placebo, and increased survival was attributed to better standard of care.

CAR T-cell therapy with bb2121 induced deep, long-lasting responses in patients with heavily pretreated MM.

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma.

Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.

In this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.

A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.

The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB–IVM1a melanoma.

Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma.

Corticosteroid medications are associated with poorer outcomes of therapy with immune checkpoint inhibitors for patients with lung cancer.

Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.

Pembrolizumab monotherapy showed promising antitumor activity in clear cell RCC in the phase II KEYNOTE-427 trial.

Patients treated for RCC with atezolizumab plus bevacizumab reported fewer impacts to daily function and quality of life than those on sunitinib.

In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.

Administering pembrolizumab before EGFR TKIs may be inappropriate for TKI-naive patients with EGFR-mutant NSCLC.

In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.

Adding pembrolizumab to pemetrexed and carboplatin for advanced nonsquamous NSCLC is associated with improved overall survival at 24 months.

Pembrolizumab represents a new standard first-line treatment option for PD-L1–expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.

In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.

Combining the ALK inhibitor with this immunotherapeutic agent had an acceptable safety profile and yielded an ORR of 85.7%, South Korean investigators reported.

The addition of atezolizumab to chemotherapy was associated with superior PFS but did not improve preliminary OS.

In this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.

Obese patients survived longer during immune checkpoint blockade for metastatic lung cancer compared with underweight patients and those who lost weight during treatment.

Pembrolizumab has shown activity against some lung cancer metastases in the brain, but responses can be discordant with extracranial tumor responses.